Answers are grounded in this paper and cite their sources.
Multiple Myeloma (MM) is a hematologic malignancy characterized by abnormal plasma cell proliferation, often leading to kidney dysfunction. Cystatin-C, a reliable marker of renal function unaffected by age, gender, or muscle mass, has been proposed as a tool for early detection of kidney dysfunction and prognosis prediction. However, evidence regarding its role as an independent prognostic factor in MM remains inconsistent. To evaluate the potential of Cystatin-C as an independent prognostic factor for kidney dysfunction in MM patients. This systematic review and meta-analysis followed PRISMA 2020 guidelines and was registered with PROSPERO (CRD42024629211). Risk of bias was assessed using the Newcastle-Ottawa Scale and JBI Critical Appraisal Tools. Data were analyzed with Review Manager 5.4. Cystatin-C levels were significantly higher in MM patients than in healthy controls (SMD = 0.59; 95% CI: 0.41–0.78; p < 0.00001). In addition, higher Cystatin-C levels were associated with advanced ISS stages (MD =-1.11; 95% CI: -1.81 to -0.40; p = 0.002), and the proportion of patients with elevated levels increased progressively with disease stage (OR = 0.06; 95% CI: 0.02–0.20; p < 0.0001). By contrast, the association between elevated Cystatin-C and overall survival did not reach statistical significance (HR=1.76; 95%CI:0.10–29.64; p=0.70). Cystatin-C demonstrates utility as a marker of kidney dysfunction in MM and may help differentiate disease stages according to ISS criteria. However, its role as an independent prognostic factor for survival remains unconfirmed, highlighting the need for larger, prospective studies incorporating multivariate analyses.
No takes yet. Share an insight, caveat, or question.
Kurniawan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: